Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Therapeutic Target for Treatment of Ataxia

Technology #20160307

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Ataxic movement disordersCerebellumCerebellum cells
Categories
Researchers
Harry T. Orr, PhD
Professor, Department of Laboratory Medicine and Pathology
External Link (www.neuroscience.umn.edu)
Managed By
Kevin Anderson
Technology Licensing Officer 612-624-8293
Patent Protection

US Patent Pending 20170252334A1
Publications
Cerebellar Transcriptome Profiles of ATXN1 Transgenic Mice Reveal SCA1 Disease Progression and Protection Pathways
Neuron, Volume 89, Issue 6, 16 March 2016, Pages 1194-1207

Elevated Cck expression protects Purkinje cells

A cholecystokinin receptor (Cck1R) agonist may treat symptoms of ataxia. Cerebellar ataxia disorders occur when cerebellar Purkinje cells degenerate and die. The protective pathway identified involves upregulating the Cck gene by administering a Cck1R agonist. When Cck (or Cck1R) was knocked out in mice models, the mice showed progressive ataxia, Purkinje cell degeneration and death, but administering a Cck1R agonist activated Cck1R to protect against progressive disease. The Cck-Cck1R pathway represents a therapeutic target for protecting the Purkinje cells against atrophy and death. It may be an effective treatment for patients suffering from ataxia as well as those at risk, even before symptoms occur.

Treats and prevents ataxia

Currently no treatments can prevent or slow ataxia, and any treatments that do exist merely aim to alleviate symptoms. This method shows that upregulation of cholecystokinin (Cck) and the subsequent interaction with the Cck1 receptor halts progressive Purkinje cell pathology and can effectively treat—or even prevent—ataxia.


BENEFITS AND FEATURES:

●  Cholecystokinin receptor (Cck1R) agonist

●  Treats and may even prevent ataxia

●  Upregulates Cck gene

●  Protects Purkinje cells against atrophy and death


APPLICATIONS:

●  Patients with ataxia

●  Patients at risk of ataxia

●  Damaged Purkinje cells 


Phase of Development - Proof of concept. In vivo genetic proof of concept; in vivo pharmacology proof of concept in two genetic models of ataxia.


Interested in Licensing?
The University relies on industry partners to scale up technologies to large enough production capacity for commercial purposes. The license is available for this technology and would be for the sale, manufacture or use of products claimed by the issued patents. Please contact Kevin Anderson to share your business needs and technical interest in this technology and if you are interested in licensing the technology for further research and development.